On November 1, 2021 Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, reported that the Company will be presenting at the Connective Tissue Oncology Society, or CTOS, 2021 Virtual Annual Meeting taking place November 10-13, 2021 (Press release, Inhibrx, NOV 1, 2021, View Source [SID1234594051]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CTOS Virtual Presentation Details:
Title: Safety and Efficacy of the Tetravalent Death Receptor 5 Agonist INBRX-109 in Patients with Conventional Chondrosarcoma: Update from the Phase 1 Expansion Cohort
Lead Author: Vivek Subbiah, MD
Abstract: 1082377, (P 018)
Oral Presentation on Thursday, November 11th at 1:29 p.m. – 1:36 p.m. Eastern Time
Title: Tetravalent Death Receptor 5 Agonist INBRX-109 in Ewing Sarcoma: Planned Phase 1 Cohort Expansion Guided by Preclinical Data
Lead Author: Emily Rowell, PhD
Abstract: 1818985, (P 090)
Poster Presentation on Thursday, November 11th at 2:30 p.m. – 3:15 p.m. Eastern Time
Additionally, the Company will be presenting at the following upcoming virtual investor conferences:
The Credit Suisse 30th Annual Healthcare Conference; Tuesday, November 9th at 3:30 p.m. Eastern Time;
The Stifel 2021 Healthcare Conference; Tuesday, November 16th at 10:00 a.m. Eastern Time;
The Jefferies London Healthcare Conference; November 16th–19th; Pre-recorded for conference attendees and available post-conference on Inhibrx’s website;
The Evercore ISI 4th Annual HealthCONx Conference; Wednesday, December 1st at 3:30 p.m. Eastern Time; and
The JMP Securities Hematology and Oncology Summit; Tuesday, December 7th at 2:00 p.m. Eastern Time.
The scientific posters and presentation will be accessible through a link on the investors section of Inhibrx’s website at View Source The investor conference presentations will be webcast live and will also be accessible through the same link. The webcasts will be available for at least 60 days following the event.